Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections

被引:85
|
作者
Lestner, Jodi [1 ]
Hope, William W. [2 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Fac Med, London, England
[2] Univ Liverpool, Dept Mol & Clin Pharmacol, Liverpool L69 3GE, Merseyside, England
基金
英国医学研究理事会; 美国国家卫生研究院;
关键词
antifungal; itraconazole; pharmacodynamics; pharmacokinetics; toxicodynamics; RESISTANT ASPERGILLUS-FUMIGATUS; HYDROXYPROPYL-BETA-CYCLODEXTRIN; STEADY-STATE PHARMACOKINETICS; DRUG-DRUG INTERACTION; CANDIDA-ALBICANS; DISEASES-SOCIETY; IN-VITRO; PRACTICE GUIDELINES; ORAL ITRACONAZOLE; AZOLE RESISTANCE;
D O I
10.1517/17425255.2013.794785
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Introduction: Fungal infections are a major source of global morbidity and mortality. Itraconazole is a triazole antifungal agent that is widely used for the prevention and treatment of fungal infection. While newer antifungal agents are now available, itraconazole is an orally bioavailable agent with broad-spectrum antifungal activity. Itraconazole remains a useful drug for the management of allergic and invasive mycoses worldwide. Areas covered: This article provides a summary of the pharmacokinetics, pharmacodynamics and clinical uses of itraconazole. Additionally, the authors summarise the safety and recently described toxicodynamics and discuss the value of therapeutic drug monitoring (TDM) with itraconazole. The following search criteria were constructed in order to identify relevant literature using PubMed and Ovid-MEDLINE: itraconazole, triazole, pharmacokinetics, pharmacodynamics, toxicodynamics and TDM. Relevant abstracts and articles identified from reviewing secondary citations were additionally retrieved and included if relevant. Expert opinion: Itraconazole remains an important agent in the prevention and treatment of fungal infection. Itraconazole has a broad-spectrum of activity and is available in both an intravenous and oral form making long-term use in chronic mycoses practical. Itraconazole is widely used for the treatment of endemic fungal infections. Pharmacokinetic variability and clinically important drug interactions make TDM of itraconazole an important consideration.
引用
收藏
页码:911 / 926
页数:16
相关论文
共 50 条
  • [21] Treatment of allergic fungal sinusitis with high-dose itraconazole
    Rains, BM
    Mineck, CW
    AMERICAN JOURNAL OF RHINOLOGY, 2003, 17 (01): : 1 - 8
  • [22] Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole
    Glasmacher, A
    Hahn, C
    Leutner, C
    Molitor, E
    Wardelmann, E
    Losem, C
    Sauerbruch, T
    Marklein, G
    Schmidt-Wolf, IGH
    MYCOSES, 1999, 42 (7-8) : 443 - 451
  • [23] Pharmacology of Liposomal Amphotericin B: An Introduction to Preclinical and Clinical Advances for Treatment of Life-threatening Invasive Fungal Infections
    Walsh, Thomas J.
    Lewis, Russell E.
    Adler-Moore, Jill
    CLINICAL INFECTIOUS DISEASES, 2019, 68 : S241 - S243
  • [24] Cost Effectiveness of Posaconazole vs. Fluconazole/Itraconazole in Prophylactic Treatment of Invasive Fungal Infections in Mexico
    Rely, Kely
    Alexandre, Pierre K.
    Salinas Escudero, Guillermo
    VALUE IN HEALTH, 2011, 14 (05) : S39 - S42
  • [25] Clinical Experience in Invasive Fungal Infections
    Patrícia Pacheco
    Ana Sofia Ventura
    Teresa Branco
    Lucília Gonçalves
    Célia Carvalho
    Clinical Drug Investigation, 2013, 33 : 23 - 26
  • [26] Clinical Experience in Invasive Fungal Infections
    Pacheco, Patricia
    Ventura, Ana Sofia
    Branco, Teresa
    Goncalves, Lucilia
    Carvalho, Celia
    CLINICAL DRUG INVESTIGATION, 2013, 33 : S23 - S26
  • [27] Update on therapeutic approaches for invasive fungal infections in adults
    Boutin, Catherine-Audrey
    Luong, Me-Linh
    THERAPEUTIC ADVANCES IN INFECTIOUS DISEASE, 2024, 11
  • [28] Critically ill patients and invasive fungal infections: an update
    Borges, M.
    MYCOSES, 2011, 54 : 39 - 39
  • [29] Treatment ef invasive fungal infections
    Warnock, DW
    HOSPITAL MEDICINE, 1998, 59 (04): : 266 - 267
  • [30] Agents for treatment of invasive fungal infections
    Luna, B
    Drew, RH
    Perfect, JR
    OTOLARYNGOLOGIC CLINICS OF NORTH AMERICA, 2000, 33 (02) : 277 - +